Особенности диагностики и лечения HBeAg-негативного хронического гепатита В
Диссертация
Основу противовирусной терапии составляет интерферон-а, компенсирующий дефицит эндогенного интерферона при ХГВ. Однако значительная-часть больных ХГВ изначально не реагируют на лечение интерфероном, или результаты лечения оказываются нестойкими. В связи с этим существенный интерес представляет собой новая группа противовирусных средств — аналоги нуклеозидов. В основе их действия лежит подавление… Читать ещё >
Список литературы
- Абдурахманов Д.Т. Клинико-морфологическая характеристика хронического гепатита В // Автореф. дис. докт. мед. наук. М., 2003.
- Апросина З.Г., Игнатова Т. М., Козловская JI.B. Хронический вирусный гепатит // Под редакцией Серова В. В., Апросиной З. Г. М.: Медицина, -2002.-384 с.
- Балаян М.С., Михайлов М. И. Энциклопедический словарь вирусные гепатиты. -М.: Новая слобода, — 1994. — 428 с.
- Баранов A.A., Каганов Б. С., Потапов A.C. Хронический гепатит В у детей // Вопросы современной педиатрии 2002. Т.1. — № 3- С. 46.
- Брико Н.И., Филатов H.H., Шаханина И. Л. Клинико-эпидемиологическая характеристика и основные направления профилактики гепатита В // Клиническая фармакология и терапия. — 2000.-Т. 9. -№ 1.
- Волкова М.А. Интерфероны и их противовирусное действие. // Вирусные гепатиты. Инф. Бюллетень, 1999. — № 2 (6). — С. 3−11.
- Горбаков В.В. Современные подходы к лечению хронических вирусных заболеваний печени // Терапевтический архив.- 2000. — № 8. — С. 5−9.
- Горбаков B.B. Хронические вирусные гепатиты // Нов. мед. журнал. -1996.-№ 5−6.-С. 24−27.
- Де Клерк Э. Перспективы лечения вирусного гепатита В.// Клиническая микробиология и антимикробная химиотерапия 2000. Т. 2. — № 3 — С. 5.
- Дубинина И.Г. Использование метода полимеразной цепной реакции в клинико-диагностических лабораториях // Лаборатория. 1996. — № 4. -С. 3−6.
- Ершов Ф. И., Чижов Л. П., Тазулахова Э. Б.// Противовирусные средства. СПб. — 1993. — 104 с.
- Жданов К. В. Латентные формы вирусных гепатитов В и С у лиц молодого возраста. Дис.. докт. Мед. наук, — СПб. — 2000. — С. 18−31.
- Ильина E.H. Особенности генодиагностики трансфузионных вирусных гепатитов// НИИ ФХМ, НПФ «Литех"// Сборник материалов научно-практической конференции. Красногорск — 2004. — С. 9−16.
- Каршиева A.B. Отдаленные (пятилетние) результаты лечения интерфероном альфа-2а больных хроническим гепатитом С. // Дисс.. канд. мед наук, — Москва, — 2001. — С. 27−29 .
- Кузнецов В.П. Интерфероны как средство иммуномодуляции // Иммунология. 1987. — № 4. — С. 30−34.
- Кузнецов В.П. Современное состояние проблемы интерферона //Антибиотики и химиотерапия. 1989. — Т. 34. — № 9. — С. 152−646.
- Лок A.C., Макмахон Дж. Б. Практические рекомендации Американской ассоциации по изучению заболеваний печени.// Клиническая микробиология антимикробная химиотерапия. 2002. — Т.4. — № 2. — С. 164−186.
- Майер К.-П. Гепатит и последствия гепатита.: Практич. рук.: Пер. с нем./ Под ред. Шептулина A.A. М: ГЭОТАР Медицина. — 1999. — 423 с.
- Окороков А.Н. Диагностика болезней внутренних органов: Т. 1. Диагностика болезней органов пищеварения: М.: Мед. лит. — 2000 — С. 297−306.
- Онищенко Г. Г. О проблемах реализации закона «О санитарно-эпидемиологическом благополучии населения». Здравоохранение Российской Федерации, 2001. — № 3. — С. 3−8.
- Подымова С.Д. Болезни печени: руководство для врачей. Издание третье, переработанное и дополненное. М., Медицина, 1998. — 704 с.
- Скворцов C.B. Применение цепной полимеразной реакции в диагностике вирусного гепатита В.// Российский журнал гастроэнтерологии, гепатологии.-1994. — № 2.— С. 108−110.
- Соринсон С.Н. Вирусные гепатиты. СПб.: ТЕЗА. — 1998. — С. 56−63.
- Сторожаков Г. И., Никитин И. Г., Поляков А. Н. хронический гепатит, ассоциированный с вирусом гепатита В с наличием мутации в рге-соге области: клиника и подходы к терапии // Клиническая фармакология и терапия. 2000. — Т. 9. — № 1. — С. 45−48.
- Томас Н.С., Карман В. Ф. (Н. С. Thomas, W. F. Carman). Оболочечный и прекоровый/коровый варианты HBV // Российский журнал гастроэнтерологии, гепатологии. 1994 — № 2. — С. 53−60.
- Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Практическое руководство.: пер. с англ./ Под редакцией Апросиной З. Г., Мухина Н. А. М.: ГЕОТАР-МЕД. — 2002. — 313−315.
- Ющук Н.Д., Царегородцев А. Д. Лекции по инфекционным болезням. Москва, 1996.
- Akarca U.S., Lok A.S. Naturally occurring hepatitis В viruses core gene mutations // Hepatology. 1995. — Vol. 22. — P. 50−60.
- Alexander G J., Brahm J., Fagan E.A., Smith H.M., Daniels H.M., Eddleston A.L., Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis В virus infection // Lancet. 1987. — Vol. 8550. — P. 66−69.
- Alexopoulou A., Karayiannis P., Hadziyannis S.J. et al. Emergence and selection of HBV variants in an anti-HBe positive patient persistently with quasi-species // J Hepatol. 1997. — Vol. 26. — P. 748−753.
- Alter M.J., Margolis H.S. The emergence of Hepatitis B as a sexually transmitted disease // Med Clin No Amer. 1990. — Vol. 74. — P. 15 299−1541.
- Alter Miriam J. Epidemiology of hepatitis B in Europe and worldwide // EASL International Consensus Conference on Hepatitis B 2002. P. 75−77.
- Balfour H.J. Antiviral drugs // N. Engl J Med. 1999. Vol. 340. — P. 12 551 268.
- Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase // Proceedings of the National Academy of Sciences. USA 1991.-Vol. 88.-P. 189−193.
- Bellentani S., Dal Molin G., Miglioli L., Croce L., Masutti F., Castiglione A., Campello C., Tiribelli C. Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort // J Hepatol. 2002. — Vol. 36 (suppl I). — P. 228.
- Brechot C., Thiers V., Kremsdorf D., Nalpas B. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely «occult»? // J Hepatology. 2001. — Vol. 34. — P. 194−203.
- Brunetto M.R., Oliveri F., Colombatto P., Capalbo M., Barbera C. and Bonino F. Treatment of chronic anti-HBe positive hepatitis B with interferonalpha // J hepatology 1995. (Suppl. 1): 42−44.
- Brunetto M.R., Oliveri F., Colombatto P., et al. Treatment of HBeAg negative chronic hepatitis B treatment with interferon or pegylated-interferon // EASL International Consensus Conference on Hepatitis B. — 2002. — P. 273 281.
- Brunetto M.R., Giarin M., Oliveri F. et al. «e» Antigen defective Hepatitis B virus and course of chronic infection // J Hepatol. 1991. — Vol. 13 (Suppl. 4). -P. 82−86.
- Brunetto M.R., Oliveri F., Rocca G., Criscuolo D., Chiaberge E., Capalbo M., et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen // Hepatology 1989. Vol. 10.-P. 198−202.
- Brunetto M.R., Stemler M., Schodel F., et al. Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis // J. Gastroenterol. 1989. — Vol. 21. — P. 151−154.
- Buckwold V.E., Xu Z., Chen M., Yen T.S., Ou J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication // J Virol. 1996. — Vol. 70. — P. 58 455 851.
- Buti Maria, Esteban Rafael. Entecavir, FTC, LFMAU and others. // EASL International consensus conference on hepatitis B. 2002. P. 229−232.
- Carman W.F., Jacyna M.R., Hadziyannis S. et al. Mytation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection //Lancet. 1989. — Vol. 2. — P. 588−591.
- Carreno V., Castillo I., Molina J., Porres J.C., and Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy //J Hepatol.-1992.-Vol. 15.-P. 102−106.
- Chang M.H. Natural history of hepatitis B infection in children // J. Gasroenterol Hepatol. 2000. — Vol. 15. — P. l 1−19.
- Chu C.J., Hussain M., Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C //Gastroenterology 2002. Vol. 122. — P. 1756−1762.
- Chu C.M., Liaw Y.F. Intrahepatic expression of HBcAg in chronic HBV hepatitis: lessons from molecular biology // Hepatology. 1990. — Vol. 12. — P.1443−1445.
- Chung H.T., Lai C.L., Wu P.C., Lok A.S.F. Synergism of chronic alcoholism and hepatitis B infection in liver disease // J Gastroenterol Hepatol 1989. — Vol. 4.-P. 11−16.
- Chyama K., Suzuki Y., Kobayashi M. et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy // Hepatology. — 1998. -Vol. 27.-P. 1711−1716.
- Colloredo G., Bellati G., Leandro G., Colombatto P. Quantitative analysis of Ig M anti-HBc in chronic hepatitis B patients using a new «gray- zone» for the evaluation of «borderline» values // J. Hepatol. 1996. — Vol. 25 (5). -P. 644−648.
- Compton J. Nucleic acid sequence-based amplification // Nature (London), -1991.-Vol. 350.-P. 83−85.
- Cooksley G. The treatment of e antigen positive chronic hepatitis B with pegylated-interferon // EASL International Consensus Conference on Hepatitis B 2002. — P. 237−238.
- Craxi Antonio, di Bona Danilo, Camma Calogero. Interferon Alfa for the HBeAg-positive chronic hepatitis B //EASL International Consensus Conference on Hepatitis B 2002. — P. 137−142.
- Davis G.L., Hoomagle J.H., Waggoner J.G. Spontaneous reactivation of chronic hepatitis B virus infection // Gastroenterology 1984. Vol. 86. — P. 230−235.
- De Franchis R., Meucci G., Vecchi M., Tatarella M., Colombo M., Del Ninno E., Rumi M.G., Donate M.F., Rochi G. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993. — Vol. 118. — P. 191−194.
- Di Marco V., Loo Iacono O., O, Camma C., Vaccaro A. The long-term course of chronic hepatitis B // Hepatology 1999. — Vol. 30. — P. 257−264.
- Dienslag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., Crowther L., et al. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States // N Engl J. Med 1999. Vol. 341. — P. 1256−1263.
- Ehata T., Omata M., Yokosuka O. et al. Variations in codons 84−101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection // J Clin Invest. 1992. — Vol. 89. — P. 332−338.
- Ehata T., Omata M., Chuang W.L. et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis // J Clin Invest. 1993. — Vol. 91. — P. 1206−1213.
- Fattovich G., Rugge M., Brollo L., Pontisso P., Noventa F., Guido M., Alberti A., et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B // Hepatology 1986. -Vol. 6.-P. 167−172.
- Fattovich G., Brollo L., Alberti A., Realdi G., Pontisso P., Giustina G., Ruol A. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis//Liver-1990.-Vol. 10.-P. 141−146.
- Fattovich G., Giustina G., Realdi G., Corrocher R., Schalm S.W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alpha. // Hepatology 1997. — Vol. 26. — P. 1338−1342.
- Fattovich G., Rugge M., Brollo L. Clinical, virologic and histologic outcome following sero conversion from HBeAg to anti-HBe in chronic hepatitis tipe B // Hepatology 1986. — Vol. 6. — P. 167−172.
- Fong T.I., Di Bisceglie A.M., Gerber M.A., Waggoner J.C. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B //Hepatology- 1993.-Vol. 18 (6).-P. 1313−1318.
- Funk M. L, Rosenberg D. M, Lok ASF. World wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants // J Viral Hepat — 2002. — Vol. 9. — P. 52−61.
- Gilson R.J., Chopra K.V., Newell A.M. et al. A placebo- controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection // J Viral Hepatitis. 1999. — Vol. 6. — P. 387−395.
- Greenberg H. B., Pollard R. B., Lutwick L. I. Et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis // New Engl. J. Med. 1976. — Vol. 295. — P. 517 — 522.
- Greenblatt M. S., Feitelson M. A., Zhu M. et al. Integrity of p53 in hepatitis B x antigen-positive and negative hepatocellular carcinomas // Cancer Res. -1997.-Vol. 57.-P. 426−432.
- Hadziyannis S. J Hepatitis B e antigen negative chronic hepatitis B. From clinical recognition to pathogenesis and treatment //Vir Hep Rew 1995. Vol. l.-P. 7−36.
- Hadziyannis S.J., Hadziyannis E., Georgiou A. et al. HBV reactivation in anti-HBe positive HbsAg carriers // Hepatology 1992. — Vol. 16. — P. 64 A (Abstract).
- Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B // Hepatology 2000. — Vol. 32. — P. 847−851.
- Hadziyannis S.J., Vassilipoulos D. Hepatitis B e antigen-negativ chronic hepatitis B // Hepatology 2001. Vol. 34. — P. 617−624.
- Hadziyannis S., Bramou T., Makris A., Moussoulis G., Zignego L., Papaioannou C. Interferon alpha-2b treatment of HBeAg negative/serum HBV-DNA positive chronic hepatitis type B // J Hepatol. 1990. — Vol. 11 (Suppl 1).-P. 133−136.
- Heathcote J. Result of lamivudine in therapy for HBe Antigen Positive Hepatitis // EASL International Consensus Conference on Hepatitis B 2002. -P. 157−160.
- Hodinka R. L. The clinical utility of viral quantitation using molecular methods // Clin Diagn Virol. 1998. — Vol. 10. — P. 25−47.
- Honkoop P., Niesters H.G., de Man R.A., Schalm S. W. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns //
- J Hepatology. 1997. — Vol. 26, № 6. — P. 1393−1395.
- Hoofhagle J.H., Dusheiko G.M., Seeff L.B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis // Ann Intern Med 1981. — Vol. 94.-P. 744−748.
- Hoofhagle J.H., Shafritz D.A., Popper H. Chronic Type B hepatitis and the «healthy» HBsAg carrier state // Hepatology 1987. — Vol. 7. — P. 758−763.
- Hunt C.M., McGill J.M., Allen M.L., Condreay L.D. Clinical relevance of hepatitis B virus mutations // Hepatology. 2000. — Vol. 31. — P. 1037−1044.
- Isaak A., Lindemann J. Virus interference. The interferons. Proceedings of the Royal Society of London (Biology). 1957. — Vol. 147. -P.258−267.
- Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., Hoofhagle J.H. Long-term remission of chronic hepatitis B after alphainterferon therapy // Ann Intern Med. 1991 Apr 15. — Vol. 114 (8). — P. 629 634.
- Krogsgaard K. Does corticosteroid pretreatment enhance the effect of Interferon-a treatment of chronic hepatitis B // Hepatol. -1994. Vol. 20. -P. 159−162.
- Krogsgaard K., Marcelliin P., Trepo C., Berthelot. Prednisolon withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B // Hepatology 1996. — 25. — P.803−813.
- Lai C.L., Chine R.W., Leung N.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y. et al. A one year trial of lamivudine for chronic hepatitis B // N. Engl. J. Med. 1998.-Vol. 339.-P. 61−68.
- Lai C-L., Yuen M.F. Profound suppression of hepatitis B virus replication with lamivudine // J Med Virol. 2000. — Vol. 61. — P. 367−373.
- Lai C-L., Myers M.W., Pow D. M et al. Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): result of a dose-escalation trial // Hepatology. 2001. — Vol. 34. -P. 321 A.
- Lai C-L, Rosmawati M., Lao J. et al. A phase II study of entecavir vs lamivudine in adult with chronic hepatitis B // Hepatology. 2001.- Vol. -34 (Suppl. 1).-P. 24.
- Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., Kleiner D.E., et al. Long-term therapy of chronic hepatitis B with lamivudine //i Hepatology. 2000. — Vol. 32. — P. 828−834.
- Lee W.M. Hepatitis B virus infection // N Engl J Med 1997. Vol. 337. -P. 1733−1745.
- Leung N., Gish R.G., Wiang C. et al. A randomized, double-blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment // Hepatology 2001. — Vol. 34. — P. 349A.
- Leung Y.K., So T. Treatment of chronic hepatitis B using Thymosin alpha 1 and a combination of two nucleoside analogs, Lamivudine and Famciclovir. Millennium National ZADAXIN meeting on Viral Hepatitis April, 2000.
- Liaw Y.F., Leung N.W., Chang T.T., Guan R., Tai D.I., Chien R.N., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group // Gastroenterology -2000.-Vol. 19.-P. 172−180.
- Lindh M., Horal P., Dhillon A.P. et al. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen -negative stage show more severe liver damage // Hepatology. 1996. — Vol. 24. — P. 494−501.
- Lindh M. Andersson A-S., Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus — Largescale analysis using a new genotyping method // J Infect Dis. 1997. — Vol. 175. — P. 1285−1293.
- Lok A.S.F., Lai C.L., Wu P.C., Leung E.K.Y., Lam T.S. Spontaneous hepatitis e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection // Gastroenterology 1987. -Vol. 92. P. 1839−1843.
- Lok A.S., Akarca U., Green S. Mutations in the precore region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal // Proc Natl Acad Sci USA 1994. — Vol. 91. -P. 4077−4081.
- Lok A.S., Lai C.L., Wu P.C., Leung E.K. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection // Lancet. 1988. — Vol. 2. — P. 298−302.
- Lok A.S., Chung H.T., Liu V.W., Ma O.C. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha // Gastroenterology 1993. -Vol. 105 (6).-P. 1833−1838.
- Lok A.S., Heathcote E.J., Hoofiiagle J.H. Management of hepatitis B: 2000-Summary of a workshop // Gastroenterology 2001. — Vol. 120. — P. 18 281 853.
- Lok ASF, McMahon B.J. Chronic hepatitis B // Hepatology 2001. — Vol. 34. -P. 1225−1241.
- Maddrey W.C. Hepatitis B: an important public health issue // J. Med Virol 2000. Vol. 61. — P. 362−366.
- Manesis E., Papatheodoridis G. V., Sevastianos V. et al. Significance of HBV viremia levels estimated by a quantitative PCR assay in the evaluationof HBeAg negative chronic HBV infection // J Hepatol. 2001. — vol. 34 (Suppl. l).-p. 115/Abstract).
- Manesis E.K. and Hadziyannis J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B // Gastroenterology -2001.-Vol. 121. -P.101−109.
- Marcellin P., Sereni D., Sacks S. et al. Anti-HBV activity and tolerability of clevudine, a novel nucleoside analogue: initial results of a phase I/II 28-days study // Hepatology. 2001. — Vol. 34. — P. 320A.
- Marusava H., Uemoto S., Hijikata M., Ueda Y., Tanara K. Latent hepatitis virus infection in healthy individuals with antibodies to hepatitis B core antigen // Hepatology. 2000. — Vol. 31(2). — P. 488−495.
- Maruyama T., Kuwata S., Koike K. et al. Precore wild-tipe DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion // Hepatology. 1998. — Vol. 27, № l.-P. 245−253.
- Maruyama T., Omata M., Yokosuka O. et al. Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum // gastroenterology. 1985. — Vol. 89. — P. 1104−1108.
- Maynard J. E. Hepatitis B: global importance and need for control. Vaccine,-1990.- Vol. 8.-P. 18−20.
- McMahon B.J., Hoick P., Bulkow L., Snowball M.M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus // Ann IntMed2001. Vol. 135.-P. 759−768.
- Moreno-Otero R., Garsia-Sanchez A., Buey L.G. Development of cirrhosis after chronic type B hepatitis // J. Gastroenterology 1991. Vol. 86. — P. 560 564.
- Mullis K., Faloona F., Scharf S., Saiki R., Horn G., Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction // Biotechnology 1992. — Vol. 24. — P. 17−27.
- Mutimer D., Pillay D., Cook P., Ratcliffe D., O’Donnell K., Dowling D., Shaw J. et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy // J Infect Dis. 2000. — Vol. 181. -P. 713−716.
- Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B // N Engl J Med. 1996. — Vol. 334. — P. 1422−1427.
- Norder H., Hammans B., Lee S-D. et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen // J Gen Virol. — 1993. Vol. 74. — P. 1341−1348.
- Orito E., Mizokami M., Sakugawa H. et al A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group // Hepatology 2001. Vol. 33.-218−223.
- Papatheodoridis G.V., Hadziyannis S.J. Diagnosis and management of pre-core mutant chronic hepatitis B // J. of viral hepatitis. 2001. — Vol. 8. — P. 311−321.
- Papatheodoridis G.V., Manesis E., Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B // J Hepatol. 2001. — Vol. 34. — P. 306−313.
- Pastore G., Santantonio T., Milella N., Monno L., Moschetta R., Pollice L. Anti-HBe positive chronic hepatitis 3 with HBV-DNA in serum: response to a six month course of lymphoplastoid INF // J Hepatology 1992. — Vol. 11 (Suppl 1).-P. 133−136.
- Perrilo R.P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologic mediated liver disease // Gastroenterology 2001. — Vol. 120.-P. 1009−1022.
- Perrilo R.P. Chronic hepatitis B: problem patients (including patients with decompensated disease) // J. Hepatol. 1995. — Vol. 2 (Suppl. 1). — P. 45−48.
- Perrilo R.P., Tamburro C., Regenstein F. and other. Low-dose, titratable interferon- a in decompensated liver disease caused by chronic infection with hepatitis B virus // Gastroenterology 1995. — Vol. 109. — P.908−916.
- Pichoud C., Berby F., Stuyver L., Petit M.A., Trepo C., Zoulim F. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B // J Hepatol. 2000. — Vol. 32. — P. 307−316.
- Pichoud C., Seigneres B., Wang Z., Trepo C., Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance // Hepatology 1999. — Vol. 29.-P. 230−237.
- Raimando G., Balsano C., Craxi A. Occult Hepatitis B virus infection digest and liver disease // J Hepatology 2000. — Vol. 32. — P. 822−826.
- Rizzetto M., Volpes R., Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine // J Med Virol. 2000. — Vol. 61. — P. 398 402.
- Robert M.T. Chan. Treatment of HBeAg negative HBeAb positive patients with Thymosin a 1 and Lamivudine. Millennium National ZADAXIN meeting on Viral Hepatitis April, 2000.
- Rodriguez-Frias F., Buti M., Jardi R et al // Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations // Hepatology-1995.-Vol. 22.-P. 1641−1647.
- Sanantonio T., Niro G.A., Sinisi E. et al. Lamivudine/interferon combination therapy anti- HBe positive chronic hepatitis B: a controlled pilot study // J Hepatology 2002. -Vol. 36. — P. 799−804.
- Schalm S.W., Heathcote J., Cianciara J., Farrell G., Sherman M., Willems B., Dhillon A. et al. Lamivudine and alpha interferon combination treatment ofpatients with chronic hepatitis B infection: a randomised trial // Gut 2000. — Vol. 46.-P. 562−568.
- Schalm S.W. Combination therapy for chronic hepatitis B // EASL International consensus conference on hepatitis B. 2002. — P. 243−247.
- Schiff E.R., Karayalcin S., Grimm I.S., Perillo et al. Lamivudine and lamivudine/interferon combination therapy in patients with hepatitis B who previously failed interferon // J Hepatology 1998. — Vol. 28. — suppl 388A.
- Seigneres B, Pichoud C, Ahmed S. S, Hantz 0., Trepo C., Zoulim F. Evolution of Hepatitis B Virus Polymerase Gene Sequence during Famciclovir Therapy for Chronic Hepatitis B // J Infect Dis 2000. Vol. 181:1221 -1233.
- Shaw T., Locarnini S. Combination chemotherapy for hepatitis B: the final solution? // Hepatology. 2000. — Vol. 32. — P.430−432.
- Steinberg J.L., Yeo W., Zhong S. et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role // J Med Virol. 2000. — Vol. 60 (3). -P. 249−255.
- Tassopoulos N., Hadziyannis S., Cianciara J. et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy // Hepatology. 2001. — Vol. 34. — P. 340.
- Thomas H.C., Karayiannis P. and Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon // J.Hepatol. -1991. Vol. 13 (Suppl. 1). -P. 4- 7.
- Tine F., Liberati A., Craxi A., Almasio P. and Pagliaro L. Interferon treatment in patients with chronic, hepatitis B: A meta-analysis of the published literature // J Hepatol. 1993. — Vol. 18. — P. 154−162.
- Tsiang M., Rooney J.F., Toole J.J., Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy // Hepatology -1999.-Vol. 29 (6).-P. 1863−1869.
- Uaw Y.F., Chu C.M., Su I.J., Huang MJ., Lin D.Y., Chang-Chien C.S. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis // Gastroenterology 1983. — Vol. 84.-P. 216−219.
- Urdea M.S. Synthesis and characterization of branched DNA for the direct quantitative detection of CMV, HBV, HCV and HIV // Clin. Chem. 1993. -Vol. 39. P. 725−726.
- Walker et al. A Chemiluminescent DNA Probe Test Based Upon Strand Displacement Amplification (SDA). In Molecular Methods of Virus Detection (D. L. Wiedbrauk, ed.), Chapter 15, Academic Press, 1995.
- Wang C., Correy L., Leung N. et al. Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HbeAg negative / HBV DNA positive chronic hepatitis B (CHB) // Hepatology. 2001. — Vol. 34. — P. 323A.
- Wolters L.M., Hansen B.E., Niesters H.M., et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B // J Hepatol. — 2002.-Vol. 37.-P. 137−144.
- Wong D. H., Chung A. M., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a metaanalysis // Ann. Intern. Med. 1993. — Vol. 119.-P: 312−323.
- Wong J.B., Koff R.S., Tine F., Pauker S.G. Cost-effectiveness of interferonalpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B // Ann Intern Med. 1995. — VOL 122. — P. 664−675.
- Xiong X., Flores C., Yang H., Toole J J., Gibbs C.S. Mutations in hepatitis B DNA polymerase asssociated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998. Vol. 28. — P. 1669−1673.
- Yalcin K., Yildiz F., Degertekin H., Celik Y. A 12 months course of interferon and lamivudine combination therapy versus interferon monotherapy for untreated chronic hepatitis B infection // J Hepatology. -2002.-Vol. 36.-P. 494.
- Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy// Hepatology 2001. Vol. 34. — P. 785−791.
- Zarski J.P., Marcellin P., Cohard M. et al. Comparison of anti- HBe positive and HBe antigen — positive chronic hepatitis B in France. — 1994. — Vol. 20. -P. 636−640.
- Zeuzem S., de Man R.A., Honkoop P., Roth W.K. Dynamics of hepatitis B virus infection in vivo // J Hepatol. 1997. Vol. 27(3). — P. 431−436.